Taylor Wessing has advised the Amedes Group on its acquisition of the remaining 49% stake in ArchimedLife from VLSI Holding. KPMG Law advised the seller.
According to Taylor Wessing, the Amedes Group acquired the initial majority stake in Archimed Life Science in 2020, from the same seller. "With this acquisition, the Amedes Group will strengthen its competence in the field of rare metabolic diseases," the firm announced.
Archimed Life Science is a Vienna-based company that provides and develops diagnostic services ranging from inborn errors of metabolism to oncological diseases.
The Amedes Group is a medical-diagnostic services provider for patients and physicians in private practice and hospitals.
The Taylor Wessing team was led by Partner Philip Hoflehner and included Associates Bence Toro and Cezary Dominik Kinski.
The KPMG Law team was led by Partner Stefan Arnold and included Partners Kurt Fischer and Michael Petritz and Counsel Pablo Essenther.
